Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling

Kato,Yoichiro; Zembutsu,Hitoshi; Takata,Ryo; Miya,Fuyuki; Tsunoda,Tatsuhiko; Obara,Wataru; Fujioka,Tomoaki; Nakamura,Yusuke

doi:10.3892/etm.2010.166

Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling

Authors:
- Yoichiro Kato
- Hitoshi Zembutsu
- Ryo Takata
- Fuyuki Miya
- Tatsuhiko Tsunoda
- Wataru Obara
- Tomoaki Fujioka
- Yusuke Nakamura
View Affiliations

Affiliations: Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, Department of Urology, Iwate Medical University, Morioka 020-8505, Japan, Laboratory for Medical Informatics, Center for Genomic Medicine, RIKEN, Yokohama 230-0045, Japan
Published online on: November 30, 2010 https://doi.org/10.3892/etm.2010.166
Pages: 47-56

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant chemotherapy with gemcitabine and carboplatin (GC) for invasive bladder cancer increases the chance of a radical response for a subset of patients, while other patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting the response to chemotherapy with GC, the expression profiles of biopsy samples from 37 advanced bladder cancers were analyzed using a microarray consisting of 38,500 genes or ESTs. Upon analysis of 9 ‘responder’ and 9 ‘non-responder’ tumors, 12 ‘predictive’ genes were found to be significantly differentially expressed between the ‘responder’ and ‘non-responder’ groups, and a numerical prediction scoring system that clearly separated the responder group from the non-responder group was established. This system accurately predicted the drug responses of 18 of 19 additional test cases that were reserved from the original 37 cases. Moreover, a quantitative PCR-based prediction system was developed that may be feasible for routine clinical use, and the sensitivity of invasive bladder cancer to neoadjuvant chemotherapy with GC was able to be predicted by the expression patterns in this set of genes. Nearly 50% of patients treated with GC or methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) therapy have been reported to achieve complete or partial response to either of these therapies. When we applied this prediction system as well as the system for M-VAC, we expected that approximately 80% of the patients would achieve significant tumor shrinking (>60%) by selection of either the GC or M-VAC regimens. Our results suggest that the two prediction scoring systems lead to achievement of ‘personalized therapy’ for the treatment of invasive bladder cancer and should improve the quality of life for patients with this disease.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	Sternberg CN: The treatment of advanced bladder cancer. Ann Oncol. 6:113–126. 1995.
3.	Fagg SL, Dawson-Edwards P, Hughes MA, Latief TN, Rolfe EB and Fielding JW: Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer. Br J Urol. 56:296–300. 1984. View Article : Google Scholar : PubMed/NCBI
4.	Raghavan D, Pearson B, Coorey G, et al: Intravenous cis-platinum for invasive bladder cancer. Safety and feasibility of a new approach. Med J Aust. 140:276–278. 1984.PubMed/NCBI
5.	Advanced Bladder Cancer Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 361:1927–1934. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 349:859–866. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23:4602–4608. 2005.
8.	Cam K, Yildirim A, Ozveri H, Turkeri L and Akdas A: The efficacy of neoadjuvant chemotherapy in invasive bladder cancer. Int Urol Nephrol. 33:49–52. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Dogliotti L, Carteni G, Siena S, et al: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 52:134–141. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Bamias A, Moulopoulos LA, Koutras A, et al: The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer. 106:297–303. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Nikolova DN, Zembutsu H, Sechanov T, et al: Genome-wide gene expression profiles of thyroid carcinoma: identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep. 20:105–121. 2008.PubMed/NCBI
12.	Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:531–537. 1999. View Article : Google Scholar : PubMed/NCBI
13.	Takata R, Katagiri T, Kanehira M, et al: Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 11:2625–2636. 2005. View Article : Google Scholar
14.	Yamanaka Y, Tamari M, Nakahata T and Nakamura Y: Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides. Biochem Biophys Res Commun. 287:198–203. 2001. View Article : Google Scholar : PubMed/NCBI
15.	Takata R, Katagiri T, Kanehira M, et al: Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 98:113–117. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Zehorai E, Yao Z, Plotnikov A and Seger R: The subcellular localization of MEK and ERK – a novel nuclear translocation signal (NTS) paves a way to the nucleus. Mol Cell Endocrinol. 314:213–220. 2009.
17.	Matsumoto K, Nagahara T, Okano J and Murawaki Y: The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep. 20:863–872. 2008.PubMed/NCBI
18.	Yokoi K and Fidler IJ: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res. 10:2299–2306. 2004. View Article : Google Scholar : PubMed/NCBI
19.	Iwao-Koizumi K, Matoba R, Ueno N, et al: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 23:422–431. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 331:1259–1264. 1994. View Article : Google Scholar : PubMed/NCBI
21.	Cote RJ, Dunn MD, Chatterjee SJ, et al: Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 58:1090–1094. 1998.PubMed/NCBI
22.	Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW and Pauwels RP: MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer. 88:2598–2605. 2000. View Article : Google Scholar : PubMed/NCBI
23.	Stein JP, Ginsberg DA, Grossfeld GD, et al: Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 90:1072–1079. 1998. View Article : Google Scholar : PubMed/NCBI
24.	Inoue K, Slaton JW, Karashima T, et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 6:4866–4873. 2000.
25.	Rho SB, Woo JS, Chun T and Park SY: Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells. Biotechnol Lett. 31:23–28. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Gery S, Xie D, Yin D, et al: Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res. 11:7243–7254. 2005. View Article : Google Scholar : PubMed/NCBI
27.	Dao D, Frank D, Qian N, et al: IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum Mol Genet. 7:597–608. 1998. View Article : Google Scholar : PubMed/NCBI
28.	Okabe M, Szakacs G, Reimers MA, et al: Profiling SLCO and SLC22 genes in the NCI-60 cancer cell line to identify drug uptake transporters. Mol Cancer Ther. 7:3081–3091. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 350:1828–1837. 2004. View Article : Google Scholar : PubMed/NCBI
30.	Ma XJ, Wang Z, Ryan PD, et al: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 5:607–616. 2004. View Article : Google Scholar